Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
doi: 10.1213/ANE.0000000000007921
In STEP 1, patients with obesity (without diabetes) lost nearly 15% of body weight on weekly semaglutide
In comparison, obesity drugs increase GLP-1 by more than 1,000 percent
LLY also announced in mid-February 2024 that a phase 2 trial evaluating tirzepatide for liver disease metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), met its primary endpoint where up to 74% of participants achieved resolution of MASH with no worsening of fibrosis, compared to 13% on placebo
.webp)
US$ 20.30
US$ 27.97
US$ 25.43
US$ 25.56
US$ 25.51
